Shanghai Junshi Biosciences Co (1877) Q3 2024 earnings summary

Executive summary

• Operating income for Q3 2024 reached RMB485.1 million, up 53.16% year-over-year, driven by strong sales of commercialized drugs, especially TUOYI® (toripalimab), which saw a 79% year-over-year sales increase in Q3 and 60% for the first nine months.

• Net loss attributable to shareholders narrowed to RMB281.8 million for Q3 and RMB926.8 million for the first nine months, reflecting improved expense management and focused R&D investment.

• Significant regulatory milestones included new drug approvals and expanded indications for toripalimab in China, the EU, and other regions.

Financial highlights

• Operating income for the first nine months was RMB1,271.2 million, up 28.87% year-over-year.

• Net loss attributable to shareholders for the first nine months was RMB926.8 million, a reduction from RMB1,406.8 million in the prior year.

• Basic and diluted EPS for the first nine months were both -0.94 RMB, improved from -1.43 RMB year-over-year.

• Cash and cash equivalents plus financial assets for trading totaled RMB3,045 million at period end.

Outlook and guidance

• Continued focus on commercialization of core products and expansion into global markets is expected to drive future revenue growth.

• Ongoing development and regulatory submissions for late-stage and early-stage pipeline assets aim to sustain long-term growth.